Clinical Significance of Assesment of Serum miRNA-30a in Childhood Nephrotic Syndrome
1 other identifier
observational
50
0 countries
N/A
Brief Summary
Childhood nephrotic syndrome is the most frequent glomerular disease that presents during childhood,primarily owing to a disturbed immune function.This disease is characterized by alterations in selectivity at the glomerular capillary wall that lead to an inability to restrict the urinary loss of protein.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2017
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 28, 2017
CompletedFirst Posted
Study publicly available on registry
August 1, 2017
CompletedStudy Start
First participant enrolled
October 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2019
CompletedAugust 2, 2017
August 1, 2017
1.7 years
July 28, 2017
August 1, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Percentage of patients with highly expressed serum miRNA30-a in resistant cases of childhood nephrotic syndrome.
Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood.
3 days
Study Arms (5)
Group1
Steroid sensitive nephrotic syndrome(10 cases).
Group2
Steroid resistant nephrotic syndrome(10 cases).
Group3
immunosuppressive resistant nephrotic syndrome(10 cases).
Group4
Refractory nephrotic syndrome(10 cases).
Group5
Normal children as a healthy control group(5 cases).
Interventions
Specific tests Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood
Eligibility Criteria
Group1: steroid sensitive nephrotic syndrome ( 10 cases ). Group2:steroid resistant nephrotic syndrome (10 cases). Group3:immunosuppresive resistant nephrotic syndrome(10 cases). Group4:refractory nephrotic syndrome(10 cases). Group5: normal children as a healthy control group ( 5 cases ).
You may qualify if:
- Nephrotic children aged from 2 to 18 that admitted to Pediatric Hospital.
You may not qualify if:
- Congenital or infantile nephrotic syndrome
- Other kidney diseases
- Abnormal kidney function test
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Teng J, Sun F, Yu PF, Li JX, Yuan D, Chang J, Lin SH. Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis. Int J Clin Exp Pathol. 2015 Jun 1;8(6):7282-6. eCollection 2015.
PMID: 26261628BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principle investigator
Study Record Dates
First Submitted
July 28, 2017
First Posted
August 1, 2017
Study Start
October 1, 2017
Primary Completion
June 1, 2019
Study Completion
October 1, 2019
Last Updated
August 2, 2017
Record last verified: 2017-08